Axol Bioscience are specialists in the supply of human cell culture products and services. Since the company moved to Chesterford Research Park it continues to expand its range of product and service offered as well as acquiring new funding resources. They have also appointed a number of scientific experts to aid in their future endeavours.

Axol Bioscience

Early stages of Axol

Axol Bioscience was founded in 2012 by Jonathan Milner, PhD and Yichen Shi, PhD. They identified the need for innovative human cell culture products that benefit disease modelling and drug discovery. Initially, they created a platform offering customers a reliable resource of commercially available iPSC-derived neural cells, with the aim of gradually expanding this range to include all 200 cell types of the human body.

At its formation, Axol began making cells in a communal lab and relied heavily on customers and collaborators to characterise these. After some time in operation, they were approached by a large pharmaceutical company to generate a number of iPSC-derived neural cell lines. The project was successfully completed and led to Axol gaining a good reputation amongst industry members. Since then the company has grown significantly and is well known as a high-quality supplier of cell culture products gaining traction amongst the scientific community. This has meant an increase in the manufacture of existing products as well as the acquisition and commercialisation of novel technologies.

How Axol has progressed

Today, Axol Bioscience has a range of human cell culture products and services, this includes a growing range of primary and iPSC-derived cells complete with complementary culture media and supplements. Axol has also raised over £1 million through the equity crowdfunding platform, SyndicateRoom.

Axol Bioscience

“With this funding, we will diversify our product portfolio, increase our operations to meet industry demand and grow our customer base. We hope to ultimately revolutionise the drug discovery market by providing a comprehensive platform of human cells from healthy and patient donors to enable improved efficiency of the screening process and reduce animal testing”.

Yichen Shi
Axol Bioscience

After Axol’s move to Chesterford Research Park in November 2015, they have been able to expand and advance their research and development. The integrated open-plan offices and adjacent laboratory space is proving particularly advantageous, allowing the team to work alongside one another to bring state-of-the-art products to market.

“Chesterford stood out due to its location within the cluster, convenient access to major road, rail and air routes and proximity to some of the biggest pharma players in the industry.”

Yichen Shi
Axol Bioscience

At present, customers being catered to by Axol include:

  • Janssen Pharmaceutica
  • University of Cambridge
  • Harvard University
  • Kings College London
  • University of Oxford
  • Aston University

Last year the company raised £3 million last year most from a London-based VC called Calculus Capital.

Benefits of locating at Chesterford Research Park

Chesterford Research Park is located in the north of the county of Essex in the UK. It is situated within one of the region’s most important life science clusters, the South Cambridge Biotech Cluster.

The Science Village is ideal for both established and start-up companies which need flexible, high quality, self-contained accommodation. The building offers individual R&D suites ranging from 1,515 sq. ft. to 1,993 sq. ft., plus excellent scalability by combining spaces for larger occupation. Chesterford Research Park is served by high speed data connectivity and supported by a backup generator.

Chesterford Research Park boasts 60 years of continuous R&D and is now home to innovative biotech and pharmaceutical companies that produce cutting-edge technology and ground-breaking scientific discoveries.

To find out more about Chesterford Research Park see here.

Axol Bioscience


To find out more about Axol Bioscience see here.


Dave Russell-Graham

+44 (0) 7881 310776

With over 30 years’ experience in the life sciences and healthcare sector Dave has an extensive range of contacts in the industry as well as experience in pharmaceutical development through to facility refurbishment and fit out. Dave’s work has predominantly been with major pharmaceutical companies, and in 2011 he was a key player in the deal between Pfizer and Mylan for Pfizer’s respiratory technology platform. Dave is passionate about growing the sector in Essex be that through foreign direct investment, partnering with the NHS or supporting SMEs.